Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-745bb68f8f-s22k5 Total loading time: 0 Render date: 2025-01-12T04:28:09.579Z Has data issue: false hasContentIssue false

Chapter 15 - Prognostication in Neuro-Oncology and Neurological Complications of Hemato/Oncological Diseases

from Part I - Disease-Specific Prognostication

Published online by Cambridge University Press:  14 November 2024

By
Anuj Patel  and
E. Alton Sartor
Edited by
David M. Greer  and
Neha S. Dangayach
David M. Greer
Affiliation:
Boston University School of Medicine and Boston Medical Center
Neha S. Dangayach
Affiliation:
Icahn School of Medicine at Mount Sinai and Mount Sinai Health System
Get access

Summary

Metastatic brain tumors, which include both primary metastatic disease that initiated within the central nervous system (CNS) and secondary metastatic disease that started systemically and metastasized to the CNS, are collectively the most prevalent types of intracranial tumor.[1] Standardized treatment including surgery followed by either focal or whole-brain radiation have allowed for excellent local control rates.[2,3] In the setting of neurological complications related to these tumors, much work has been done to understand the key markers of prognostic and predictive significance. In addition, improved mortality rates in cancer patients have come at the cost of increasingly complicated treatment regimens including cytotoxic, immunological, surgical, and radiation-based therapies. Underlying heterogeneity across different types of metastatic brain disease is a contributing factor to this challenging decision-making process. In addition, only the presence or absence of brain metastasis at the time of initial diagnosis is noted in many historical studies, decreasing the overall detection of metastatic brain disease that develops later in the disease course.

Type
Chapter
Information
Neuroprognostication in Critical Care , pp. 219 - 228
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ostrom, QT, Patil, N, Cioffi, G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22(12 Suppl 2):iv1–iv96.CrossRefGoogle ScholarPubMed
Andrews, DW, Scott, CB, Sperduto, PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72.CrossRefGoogle ScholarPubMed
Brennan, C, Yang, TJ, Hilden, P, et al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys. 2014;88(1):130–136.CrossRefGoogle ScholarPubMed
Nayak, L, Lee, EQ, We, PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48–54.CrossRefGoogle ScholarPubMed
Tsukada, Y, Fouad, A, Pickren, JW. Lane, WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983;52:2349–54.3.0.CO;2-B>CrossRefGoogle ScholarPubMed
Barnholtz-Sloan, JS, Sloan, AE, Davis, FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–2872.CrossRefGoogle ScholarPubMed
Chinot, OL, Wick, W, Mason, W, et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–22.CrossRefGoogle ScholarPubMed
Peak, S, Abrey, LE. Chemotherapy and the treatment of brain metastases. Hematol Oncol Clin. 2006;20(6):1287–95.Google ScholarPubMed
Arvanitis, CD, Ferraro, GB, Jain, RK. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26–41.CrossRefGoogle ScholarPubMed
Soria, JC, Ohe, Y, Vansteenkiste, J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113–25.CrossRefGoogle ScholarPubMed
Davies, MA, Saiag, P, Robert, C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863–73.CrossRefGoogle Scholar
Costa, DB, Shaw, AT, Ou, SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33(17):1881.CrossRefGoogle ScholarPubMed
Wu, CT, Chen, LC, Kuo, CP, et al. A comparison of 3% hypertonic saline and mannitol for brain relaxation during elective supratentorial brain tumor surgery. Anesth Analg. 2010;110(3):903–7.CrossRefGoogle ScholarPubMed
Malik, ZA, Mir, SA, Naqash, IA, Sofi, KP, Wani, AA. A prospective, randomized, double blind study to compare the effects of equiosmolar solutions of 3% hypertonic saline and 20% mannitol on reduction of brain-bulk during elective craniotomy for supratentorial brain tumor resection. Anesthesia. 2014;8(3):388.Google ScholarPubMed
Ali, A, Tetik, A, Sabanci, PA, et al. Comparison of 3% hypertonic saline and 20% mannitol for reducing intracranial pressure in patients undergoing supratentorial brain tumor surgery: a randomized, double-blind clinical trial. J Neurosurg Anesthesiol. 2018;30(2):171–8.CrossRefGoogle ScholarPubMed
Sokhal, N, Rath, GP, Chaturvedi, A, Singh, M, Dash, HH. Comparison of 20% mannitol and 3% hypertonic saline on intracranial pressure and systemic hemodynamics. J Clin Neurosci. 2017;42:148–54.CrossRefGoogle ScholarPubMed
Vecht, CJ, Kerkhof, M, Duran-Pena, A. Seizure prognosis in brain tumors: new insights and evidence-based management. Oncologist. 2014;19 (7):751–9.CrossRefGoogle ScholarPubMed
Pruitt, AA. Medical management of patients with brain tumors. Continuum. 2015;21(2):314–31.Google ScholarPubMed
Barnholtz-Sloan, JS, Sloan, AE, Davis, FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–72.CrossRefGoogle ScholarPubMed
Johnson, JD, Young, B. Demographics of brain metastasis. Neurosurg Clin North Am. 1996;7(3):337–44.CrossRefGoogle ScholarPubMed
Stelzer, KJ. Epidemiology and prognosis of brain metastases. Surg Neurol Int. 2013;4(Suppl 4):S192.CrossRefGoogle ScholarPubMed
Gaspar, L, Scott, C, Rotman, M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–51.CrossRefGoogle ScholarPubMed
Patchell, RA, Tibbs, PA, Walsh, JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.CrossRefGoogle ScholarPubMed
Paek, SH, Audu, PB, Sperling, MR, Cho, J, Andrews, DW. Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery. 2005;56(5):1021–34.Google ScholarPubMed
Linskey, ME, Andrews, DW, Asher, AL, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):45–68.CrossRefGoogle ScholarPubMed
Chang, EL, Wefel, JS, Hess, KR, et al. in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44.CrossRefGoogle ScholarPubMed
Nayar, G, Ejikeme, T, Chongsathidkiet, P, et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget. 2017;8(42):73312.CrossRefGoogle ScholarPubMed
Groves, MD. Leptomeningeal disease. Neurosurg Clin. 2011;22(1):67–78.CrossRefGoogle ScholarPubMed
Lamba, N, Fick, T, Tewarie, RN, Broekman, ML. Management of hydrocephalus in patients with leptomeningeal metastases: an ethical approach to decision-making. J Neurooncol. 2018;140(1):5–13.CrossRefGoogle ScholarPubMed
Esquenazi, Y, Lo, VP, Lee, K. Critical care management of cerebral edema in brain tumors. J Intensive Care Med. 2017;32(1):15–24.CrossRefGoogle ScholarPubMed
Volkov, AA, Filis, AK, Vrionis, FD. Surgical treatment for leptomeningeal disease. Cancer Control. 2017;24(1):47–53.CrossRefGoogle ScholarPubMed
Lin, N, Dunn, IF, Glantz, M, et al. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case–controlled study. J Neurosurg. 2011;115(4):730–6.CrossRefGoogle ScholarPubMed
Morris, PG, Reiner, AS, Szenberg, OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012;7(2):382–5.CrossRefGoogle ScholarPubMed
Glantz, MJ, Hall, WA, Cole, BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid‐flow status. Cancer. 1995;75(12):2919–31.3.0.CO;2-9>CrossRefGoogle ScholarPubMed
Franzoi, MA, Hortobagyi, GN. Leptomeningeal carcinomatosis in patients with breast cancer. Crit Rev Oncol Hematol. 2019;135:85–94.CrossRefGoogle ScholarPubMed
Ricciardi, GR, Russo, A, Franchina, T, et al. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy-a case report and literature review. BMC Cancer. 2018;18(1):1–8.CrossRefGoogle Scholar
Brastianos, PK, Lee, EQ, Cohen, JV, et al. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020;1:1–5.Google Scholar
Louis, DN, Perry, A, Reifenberger, G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.CrossRefGoogle ScholarPubMed
Yan, H, Parsons, DW, Jin, G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.CrossRefGoogle ScholarPubMed
Hegi, ME, Diserens, AC, Gorlia, T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.CrossRefGoogle ScholarPubMed
Cairncross, JG, Wang, M, Shaw, EG, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–43.CrossRefGoogle ScholarPubMed
Marko, NF, Weil, RJ, Schroeder, JL, et al. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol. 2014;32(8):774.CrossRefGoogle ScholarPubMed
Stupp, R, Mason, WP, Van Den Bent, MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefGoogle ScholarPubMed
Wick, W, Gorlia, T, Bendszus, M, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954–63.CrossRefGoogle ScholarPubMed
Park, JK, Hodges, T, Arko, L, et alScale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28(24):3838.CrossRefGoogle ScholarPubMed
Decavèle, M, Gatulle, N, Weiss, N, et al. One-year survival of patients with high-grade glioma discharged alive from the intensive care unit. J Neurol. 2020;29:1–10.Google Scholar
Mendez, JS, Ostrom, QT, Gittleman, H, et al. The elderly left behind – changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20(5):687–94.CrossRefGoogle ScholarPubMed
Ferreri, AJ, Blay, JY, Reni, M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266–72.CrossRefGoogle ScholarPubMed
Abrey, LE, Ben-Porat, L, Panageas, KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711–15.CrossRefGoogle ScholarPubMed
Grommes, C, Rubenstein, JL, DeAngelis, LM, Ferreri, AJ, Batchelor, TT. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol. 2019;21(3):296–305.CrossRefGoogle ScholarPubMed
Jahnke, K, Thiel, E, Martus, P, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006;80(2):159–65.CrossRefGoogle ScholarPubMed
Langner-Lemercier, S, Houillier, C, Soussain, C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016 ;18(9):1297–303.CrossRefGoogle ScholarPubMed
Anderson, F, Downing, GM, Hill, J, Casorso, L, Lerch, N. Palliative Performance Scale (PPS): a new tool. J Palliat Care. 1996;12(1):5–11.CrossRefGoogle ScholarPubMed
Mei, AH, Jin, WL, Hwang, MK, et al. Value of the Palliative Performance Scale in the prognostication of advanced cancer patients in a tertiary care setting. J Palliat Med. 2013;16(8):887–93.CrossRefGoogle Scholar
Han, PK, Dieckmann, NF, Holt, C, Gutheil, C, Peters, E Factors affecting physicians’ intentions to communicate personalized prognostic information to cancer patients at the end of life: an experimental vignette study. Med Decis Making. 2016;36(6):703–13.CrossRefGoogle ScholarPubMed
Trajkovic-Vidakovic, M, de Graeff, A, Voest, EE, Teunissen, SC. Symptoms tell it all: a systematic review of the value of symptom assessment to predict survival in advanced cancer patients. Crit Rev Oncol Hematol. 2012;84(1):130–48.CrossRefGoogle ScholarPubMed
Maltoni, M, Caraceni, A, Brunelli, C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations–a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005;23(25):6240–8.CrossRefGoogle Scholar
Dolan, RD, McSorley, ST, Horgan, PG, Laird, B, McMillan, DC. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;116:134–46.CrossRefGoogle ScholarPubMed
Coudray, N, Tsirigos, A. Deep learning links histology, molecular signatures and prognosis in cancer. Nat Cancer. 2020;1(8):755–7.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×